Plenary Session I Agenda
PRESIDER: Richard Gallo, MD/PhD
3:30 PM-3:45 PM
#506, Predicting the long-term outcomes of biologics in psoriasis patients using machine learning
- S. Emam1, A. Du2, P. Surmanowicz2, S. Thomsen1, R. Griener1, R. Gniadecki2
1University of Alberta, Edmonton, Alberta, Canada, 2Medicine, University of Alberta, Edmonton, Alberta, Canada
3:45 PM-4:00 PM
#476, Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database
- R. Conic1, 2, R. Knackstedt2, G. Damiani2, B. Gastman2
1University of Maryland, Baltimore, Maryland, United States, 2Cleveland Clinic, Cleveland, Ohio, United States
4:00 PM-4:15 PM
#130, Small non-coding RNAs interact with ERK2 and effect MAPK/ERK pathway
- Z. Siprashvili1, R. M. Shenoy1, L. Elcavage1, P. Khavari1, 2
1Dermatology, Stanford University, Stanford, California, United States, 2VA Palo Alto Healthcare System, Palo Alto, California, United States
4:15 PM-4:30 PM
#861, Intravenous gentamicin therapy for junctional epidermolysis bullosa patients harboring nonsense mutations
- M. Hao1, R. Antaya2, J. Cogan1, C. Hamilton2, Y. Hou1, A. Kwong1, D. Woodley1, M. Chen1
1University of Southern California, Los Angeles, California, United States, 2Yale School of Medicine, New Haven, Connecticut, United States
4:30 PM-4:45 PM
#361, Skin-induced IL-36 triggers plasma cell IgE class switching and allergic disease
- G. J. Patrick1, H. Liu1, M. Alphonse1, D. Dikeman1, C. Youn1, J. Otterson1, Y. Wang1, A. Ravipati1, Q. Liu1, E. Raymond2, M. Ramanujam2, N. Archer1, L. S. Miller1
1Dermatology, Johns Hopkins School of Medicine, Baltimore, Maryland, United States, 2Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States